Seeking Alpha

Raptor Pharmaceutical (RPTP -1%) says it's licensed pending patents related to the use of...

Raptor Pharmaceutical (RPTP -1%) says it's licensed pending patents related to the use of cysteamine for the treatment of Rett syndrome and associated disorders of methyl-CpG binding protein 2. Under terms of the agreement, RPTP will receive exclusive global rights to develop and commercialize cysteamine and related compounds to treat diseases associated with the disorder.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs